

Recombinant human LILRB2/CD85d/ILT4 protein

Catalog Number: ATGP4042

PRODUCT INFORMATION

Expression system

HEK293

Domain

24-461aa

UniProt No.

Q8N423

NCBI Accession No.

NP_005865

Alternative Names

Leukocyte Immunoglobulin-like Receptor, CD85D, CD85d, CD85 antigen-like family member D, CD85d antigen, ILT-4, ILT4, ILT4CD85d, Ig-like transcript 4, Immunoglobulin-like transcript 4, LILRB2, LIR2, LIR-2, LIR2CD85D, Leukocyte immunoglobulin-like receptor 2, MIR10, MIR-10, MIR10LILRA6, Monocyte/macrophage immunoglobulin-like receptor 10, leukocyte immunoglobulin-like receptor subfamily B member 2, leukocyte immunoglobulin-like receptor subfamily B member 2 soluble isoform 1

PRODUCT SPECIFICATION

Molecular Weight

48.3 kDa (444aa)

Concentration

0.5mg/ml (determined by absorbance at 280nm)

Formulation

Liquid. In Phosphate-Buffered Saline (pH 7.4) containing 20% glycerol

Purity

> 95% by SDS-PAGE

Endotoxin level

< 1 EU per 1ug of protein (determined by LAL method)

Tag

His-Tag

Application

SDS-PAGE

Storage Condition

Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

BACKGROUND

Recombinant human LILRB2/CD85d/ILT4 protein

Catalog Number: ATGP4042

Description

LILRB2, also known as CD85d, LIR-2, and MIR10, is a member of the leukocyte immunoglobulin-like receptor (LIR) family. It is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. Among them it competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1. And it binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules. This protein is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Recombinant human LILRB2, fused to His-tag at C-terminus, was expressed in HEK293 cell and purified by using conventional chromatography techniques.

Amino acid Sequence


GTIPKPTLWA EPDSVITQGS PVTLSQCGSL EAQEYRLYRE KKSASWITRI RPELVKNGQF HIPSITWEHT GRYGCQYYSR
ARWSELSDDL VLVMTGAYPK PTLAQSPSPV VTSGGRVTLQ CESQVAFGGF ILCKEGEDEH PQCLNSQPHA RGSSRAIFSV
GPVSPNRRWS HRCYGYDLNS PYVWSSPSDL LELLVPGVSK KPSLSVQPGP VMAPGESLTL QCVSDVGYDR FVLYKEGERD
LRQLPGRQPQ AGLSQANFTL GPVRSYGGQ YRCYGAHNLS SECSAPSDPL DILITGQIRG TPFISVQPGP TVASGENVTL
LCQSWRQFHT FLLTKAGAAD APLRLRSIHE YPKYQAEFPM SPVTSAHAGT YRCYGSLNSD PYLLSHPSEP LELVVSGPSM
GSSPPPTGPI STPAGPEDQP LTPTGSDPQS GLGRHLGV<HH HHHH>

General References

Fanger, N.A. et al. (1998) Eur. J. Immunol. 28:3423.
Baudhuin, J. et al. (2013) Proc. Natl. Acad. Sci. USA 110:17957-17962.
Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:8856-8861.
Borges, L. et al. (1997) J. Immunol. 159:5192-5196.

DATA

SDS-PAGE



3ug by SDS-PAGE under reducing condition and visualized by coomassie blue stain